ARTICLE | Company News

Houghten deal

July 25, 1994 7:00 AM UTC

Houghten and Northwest NeuroLogic Inc. will collaborate to screen compounds for Houghten's cytokine restraining program. Northwest will use its receptor assays to screen Houghten's combinatorial libraries and individual compounds to develop drugs to treat inflammatory diseases and pigmentation disorders.

Houghten retains all rights to anti-inflammatory compounds, and Northwest will have rights to all compounds in pigmentation and hair treatment. ...